A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

NCT02419859 ↗

Completed 20 enrolled CeQur Corporation

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Timeline

Start: 2015-02
Primary completion: 2015-11
Completion: 2015-11

Publications

Mader JK, Lilly LC, Aberer F, Poettler T, Johns D, Trautmann M, Warner JL, Pieber TR. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with Type 2 diabetes. Diabet Med. 2018 Oct;35(10):1448-1456. doi: 10.1111/dme.13708. Epub 2018 Jul 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	insulin aspart	Protein / enzyme biologic	20 unknown	Subcutaneous
Subject	insulin aspart	Protein / enzyme biologic	24 unknown	Subcutaneous
Subject	insulin aspart	Protein / enzyme biologic	32 unknown	Subcutaneous
Subject	insulin aspart	Protein / enzyme biologic	40 unknown	Subcutaneous
Subject	insulin aspart	Protein / enzyme biologic	50 unknown	Subcutaneous

A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Publications

Drugs

Indications